Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study.

  title={Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study.},
  author={Ren{\'e}S. Kahn and Inge Winter van Rossum and Stefan Leucht and Philip K. McGuire and S. Lewis and Marion Leboyer and Celso Arango and Paola Dazzan and Richard James Drake and Stephan Heres and Covadonga M. D{\'i}az-Caneja and Dan Rujescu and Mark Weiser and Silvana Galderisi and Birte Yding Glenth{\o}j and Marinus J. C. Eijkemans and W. Wolfgang Fleischhacker and Shitij Kapur and Iris E. C. Sommer},
  journal={The lancet. Psychiatry},
  volume={5 10},

Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia.

Switching "non-improvers" from amisulpride to olanzapine or vice-versa increased remission rates and was safe and the superiority in the primary outcome was not paralleled by significant differences in most secondary efficacy outcomes and the effect was only apparent at the last visit making replications of longer duration necessary.

Clozapine and paliperidone palmitate antipsychotic combination in treatment-resistant schizophrenia and other psychotic disorders: A retrospective 6-month mirror-image study

This study provides the first evidence that combining clozapine with paliperidone palmitate in patients with TRS and other psychotic disorders could be effective and safe, suggesting further research with randomized controlled trials of augmentation strategies for clozAPine nonresponder patients.

A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design

It is hypothesize that patients treated with amisulpride plus olanzapine show greater improvement on the Positive and Negative Syndrome Scale total score after 8 weeks versus either monotherapy, informing an evidence-based recommendation regarding specific antipsychotic combination treatment.

Clinical Usefulness of Amisulpride Add-on Therapy in Schizophrenia Patients without Treatment Response to Second-generation Antipsychotics

The results suggested that augmentation of second-generation antipsychotics with amisulpride could be a useful option for patients with schizophrenia unresponsive to second- Generation antipsychotic treatment.



Atypical and Conventional Antipsychotic Drugs in Treatment-Naive First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine Vs Chlorpromazine

While the CLZ group showed significantly less symptomatology on some measures and fewer side effects at 12 weeks, the two treatment groups seemed to converge by 1 year, and both the rate of first achieving remission and the odds for being in remission during the trial were almost doubled for theCLZ group in comparison with the CPZ group.

Antipsychotic Drug Treatment in First-Episode Psychosis: Should Patients be Switched to a Different Antipsychotic Drug After 2, 4, or 6 Weeks of Nonresponse?

Although it is confirmed that 2-week measures of response are associated with remission, the prediction of remission is significantly improved by the inclusion of 4- and 6-week assessments, however, it is uncertain whether this improvement is clinically relevant.

Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia

This is the first study to prospectively show that early response/non-response to an antipsychotic (risperidone) is a reliable clinical marker of subsequent clinical outcomes and that a ‘switching’ strategy based on this information may lead to greater clinical improvement than staying on a drug for a longer period in some patients.

An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.

A high response rate (75%) to initial antipsychotic treatment in first-episode schizophrenia is confirmed and a subsequent trial with clozapine is clearly warranted, although it remains unclear whether outcome would be further enhanced if it were used earlier in the treatment algorithm.

Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre 1H-MRS study (OPTiMiSE)

Previous evidence linking higher levels of ACC glutamate with a poor antipsychotic response is linked with more severe symptoms at presentation and a lower likelihood of being in remission at 4 weeks is extended by showing that the association is evident before the initiation of treatment.

Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation

Substantial delays to clozapine initiation remain and antipsychotic polypharmacy and high doses are commonly used prior to clazapine, despite treatment guidelines.

On the concept of remission in schizophrenia

The new remission criteria proved to be an achievable goal for clinical trials and a consensus on the application of their time component is still needed.